Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling
Protocol ID
BLU-285-3101
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapse/refractory
Location
NSW, VIC
Sponsor
Blueprint Medicines Corporation
Links
Trial Status
Open
Sites
Sydney Children's Hospital
Royal Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
2 Years to 17 Years
International registry ID's
NCT04773782
| Study Title | A Phase 1/2 Single-arm Study to Evaluate the Safety Pharmacokinetics and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling |
|---|---|
| Protocol ID | BLU-285-3101 |
| Disease (Sub Disease) | Solid tumours |
| Diagnosis Stage | Relapse/refractory |
| Location | NSW / VIC |
| Sponsor | Blueprint Medicines Corporation |
| Links | https://clinicaltrials.gov/ct2/show/NCT04773782 |
| Trial Status | Open |
| Trial Open Date | 14/10/2022 |
| Sites | Sydney Children's Hospital / Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 2 Years to 17 Years |
| International registry ID's | NCT04773782 |